AUPH - Aurinia Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Aurinia Pharmaceuticals Inc.

4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8

Full Time Employees20

Key Executives

Dr. Richard M. Glickman L.L.D. (Hon)Founder, Chairman & CEO88.42kN/A59
Mr. Michael R. MartinCo-Founder and Chief Operating Officer280.66kN/AN/A
Mr. Dennis Bourgeault C.A.Chief Financial Officer and Sec.261.3kN/AN/A
Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)Exec. VP of Corp. Devel.257.46kN/AN/A
Dr. Neil Solomons M.D.Chief Medical Officer334.8kN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Corporate Governance

Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.